Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GENETRON HOLDINGS LIMITED

(GTH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Genetron : Health Reports Second Quarter 2021 Unaudited Financial Results (Form 6-K)

08/24/2021 | 07:55am EDT

Genetron Health Reports Second Quarter 2021 Unaudited Financial Results

BEIJING, China, August 24, 2021 - Genetron Holdings Limited ('Genetron Health' or the 'Company', NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the second quarter ended June 30, 2021.

Second Quarter and Recent Highlights

Recorded total revenue of RMB 140.5 million (US$21.8 million) for the second quarter 2021, representing a 38.1% increase over the same period of 2020.

Generated LDT segment revenue with year on year growth of 15.0% to RMB 87.1 million (US$13.5 million) for the second quarter 2021.

IVD revenue was RMB 43.8 million (US$6.8 million) for the second quarter 2021, representing 141.5% growth over the same period of 2020, due to increasing sales of Genetron S5 instrument and 8-gene Lung Cancer Assay (Tissue).

Development services grew 21.8% compared to a year ago, based on our increasing effort in providing services to biopharmaceutical partners.

Achieved gross margin of 67.2% for the second quarter 2021, compared to 63.1% in the same period of 2020, thanks to improvements in both LDT and IVD business lines.

Genetron established a IVD partnership with Shanghai Yikon Genomics Technology Co., Ltd., in which the partner will have exclusive rights of its S5 instrument in the area of reproductive health.

Recently, Seq-MRD for hematologic cancers has signed on a leading pharmaceutical MNC for use in their clinical trial.

AYVAKIT® companion diagnostic kit, developed in partnership with CStone Pharmaceuticals, has entered the priority review and approval process under the NMPA in China.

Received CE Mark for 8-gene Lung Cancer Assay (Tissue).

Established collaboration with Guizhou Province's Dafang County authorities to use HCCscreenTM for high-risk liver cancer patients in the rural markets.

Genetron's Beijing lab achieved full marks and was ranked first in NCCL's External Quality Assessment of participating clinical laboratories in China, based on its NGS-based comprehensive genomic profiling for solid tumors, Onco Panscan.

'In the second quarter, we delivered strong revenues, along with improved gross margins. We were pleased to see continued sales momentum across all of our business lines,' remarked Mr. Sizhen Wang, co-founder and CEO of Genetron Health. 'Over the past several weeks, the stricter COVID policies in China have impacted our business, which at present we believe is temporary. We are closely monitoring the evolving situation and remain focused on executing our strategy in geographies and segments that are less affected by the restrictions. Notwithstanding the near-term challenges, we also continue to execute on the pipeline front in the second half. We are moving along with our NMPA registrational trial preparation for HCCscreenTM, and we project to release CRC data for early screening later this year. Our efforts in MRD are also progressing - with the upcoming LDT launch of Seq-MRD in blood cancers in the clinical settings, as well as other ongoing studies in solid tumors. As we continue to focus on achieving the important milestones for the company, we also remain confident about the overall growth prospects of the precision oncology sector in China, thanks to continued government support and related policy tailwinds that aim at providing broader and better healthcare options for Chinese citizens.'

Second Quarter 2021 Unaudited Preliminary Financial Results

1

Total revenue for the second quarter 2021 increased by 38.1% to RMB140.5 million (US$21.8 million) from RMB101.7 million in the same period of 2020.

Diagnosis and monitoring revenue increased by 39.4% to RMB131.0 million (US$20.3 million) in the second quarter 2021 from RMB93.9 million in the same period of 2020. The increase was driven by the growth in the revenue generated from the sale of IVD products.

Revenue generated from the provision of LDT services increased by 15.0% to RMB87.1 million (US$13.5 million) during the second quarter 2021 from RMB75.8 million in the same period of 2020. In the second quarter, sales of LDT services included sales of our early screening test, HCCscreen. LDT diagnostic tests sold in the second quarter 2021 totaled approximately 6,840 units.

Revenue generated from sales of IVD products increased by 141.5% to RMB43.8 million (US$6.8 million) in the second quarter 2021 from RMB18.1 million in the second quarter 2020, due to increasing sales of Genetron S5 instrument and 8-gene Lung Cancer Assay (Tissue).

Contracted in-hospital partners

(as of the end of the period indicated)

2Q20 3Q20 4Q20 1Q21 2Q21

IVD In-hospital partners

18 20 22 23 28
2Q20 3Q20 4Q20 1Q21 2Q21

Total in-hospital partners(1)

35 38 40 42 50

Note:

(1)

The number of total in-hospital partners include both sales of LDT services and IVD products.

Revenue generated from development services increased by 21.8% to RMB9.5 million (US$1.5 million) in the second quarter 2021, from RMB7.8 million in the same period of 2020. Biopharmaceutical revenue growth increased significantly in the second quarter of 2021 compared to the same period of 2020.

Cost of revenue increased by 22.7% to RMB46.0 million (US$7.1 million) for the three months ended June 30, 2021, compared to RMB37.5 million in the same period of 2020.

Gross profit increased by 47.1% to RMB94.5 million (US$14.6 million) in the second quarter 2021 from RMB64.2 million in the same period of 2020. Gross margin improved to 67.2% for the second quarter 2021, compared to 63.1% in the same period of 2020, mainly due to higher gross margins for both LDT and IVD business lines.

Operating expenses increased by 65.8% to RMB194.6 million (US$30.1 million) for the three months ended June 30, 2021, from RMB117.4 million in the same period of 2020.

2

Selling expenses increased by 46.0% to RMB88.5 million (US$13.7 million) in the second quarter 2021 from RMB60.6 million in the same period of 2020. Selling expenses as a percentage of revenues was 63.0% in the second quarter 2021, compared to 59.6% in the same period of 2020. The increase was primarily due to higher marketing expense and higher employee compensation expenses.

Administrative expenses increased by 95.6% to RMB54.6 million (US$8.5million) in the second quarter 2021 from RMB27.9 million in the same period of 2020. Administrative expenses as a percentage of revenues increased to 38.8% in the second quarter 2021 from 27.4% in the second quarter 2020. The increases were mainly due to more headcount, higher professional fees, and IT expenses.

Research and development expenses increased by 88.2% to RMB56.2 million (US$8.7 million) in the second quarter 2021 from RMB29.8 million in the same period of 2020. Research and development expenses as a percentage of revenues increased to 40.0% in the second quarter of 2021 from 29.3% in the same period of 2020. The increases were driven by higher R&D headcount and related expenses, as well as continued innovation efforts including product development and clinical trial activities.

As a result of the above, operating loss was RMB100.2 million (US$15.5 million) for the three months ended June 30, 2021, compared to RMB53.1 million for the three months ended June 30, 2020.

Net finance income increased to RMB8.0 million (US$1.2 million) in the second quarter 2021 from net finance costs of RMB0.6 million in the same period of 2020. The increase was mainly driven by the foreign currency exchange gain.

Loss for the period was RMB92.1 million (US$14.3 million) for the three months ended June 30, 2021, compared to RMB2,832.4 million for the three months ended June 30, 2020. The Company recorded RMB2,778.6 million and nil in fair value loss of financial instruments with preferred rights for the three months ended June 30, 2020 and 2021, respectively.

Non-IFRS loss for the period, defined as loss for the period excluding share-based compensation expenses, fair value change and other loss of financial instruments with preferred rights, was RMB79.6 million (US$12.3 million) for the three months ended June 30, 2021, compared to RMB43.9 million for the three months ended June 30, 2020. Please refer to the section in this press release titled 'Non-IFRS Financial Measures' for details.

Basic loss per ordinary share attributable to ordinary shareholders of the Companywas RMB0.20 (US$0.03) for the second quarter of 2021, compared with a basic loss per share attributable to ordinary shareholders of the Company of RMB17.04 for the same period of 2020. Excluding share-based compensation expenses, fair value change of financial instruments with preferred rights and other loss of financial instruments with preferred rights, non-IFRS basic loss per share attributable to ordinary shareholders of the Company was RMB0.17 (US$0.03) for the second quarter of 2021, compared with non-IFRS basic loss per share attributable to ordinary shareholders of the Company of RMB0.26 for the same period of 2020. Diluted loss per share attributable to ordinary shareholders of the Company is equivalent to basic loss per share attributable to ordinary shareholders of the Company. Each ADS represents of five ordinary shares, par value US$0.00002 per share. Please refer to the section in this press release titled 'Non-IFRS Financial Measures' for details.

As of June 30, 2021, our cash and cash equivalents, restricted cash and current financial assets at fair value through profit or loss were RMB1,214.0 million (US$188.0 million), compared to RMB1,516.1 million as of December 31, 2020. The total decrease was mainly used for operating activities.

3

2021 Financial Guidance

At this time, we expect the current COVID-related restrictions to be temporary, and are maintaining our 2021 expected revenue range of RMB615 million to RMB625 million. However, if the current environment sustains or worsens, the Company expects to reassess its financial projections and would provide appropriate updates to the market at that time.

Conference Call

A conference call and webcast to discuss the results will be held at 8:30 a.m. U.S. Eastern Time on August 24, 2021 (or at 8:30 pm Beijing Time on August 24, 2021). Interested parties may listen to the conference call by dialing numbers below:

United States: +1-845-675-0437
China Domestic: 400-620-8038
Hong Kong: +852-3018-6771
International: +65-6713-5090
Conference ID: 7494097

Participants are encouraged to dial into the call at least 15 minutes in advance due to high call volumes.

A replay will be accessible through August 31, 2021 by dialing the following numbers:

United States: +1-855-452-5696
International: +61-2-8199-0299
Conference ID: 7494097

A simultaneous webcast of the conference call will be available on the 'News and Presentations' page of the Investors section of the Company's website. A replay of the webcast will be available for 30 days following the event. For more information, please visit ir.genetronhealth.com.

Exchange Rate Information

All translations made in the financial statements or elsewhere in this press release made from RMB into United States dollars ('US$') are solely for convenience and calculated at the rate of US$1.00=RMB 6.4566, representing the exchange rate as of June 30, 2021, set forth in the H.10 statistical release of the U.S. Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate, or at any other rate, on June 30, 2021.

Non-IFRS Financial Measures

The Company uses non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period, which are non-IFRS financial measures, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company help identify underlying trends in the Company's business that could otherwise be distorted by the effect of certain expenses that the Company includes in its loss for the year/period. The Company believes that non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period provide useful information about its results of operations, enhances the overall understanding of its past performance and future prospects and allows for greater visibility with respect to key metrics used by its management in its financial and operational decision-making.

4

Non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period should not be considered in isolation or construed as an alternative to operating profit, loss for the year/period or any other measure of performance or as an indicator of its operating performance. Investors are encouraged to review non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period and the reconciliation to its most directly comparable IFRS measures. Non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to the Company's data. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period represent loss for the year/period excluding share-based compensation expenses, fair value change of financial instruments with preferred rights and other loss of financial instruments with preferred rights (if applicable).

Please see the 'Unaudited Non-IFRS Financial Measures' included in this press release for a full reconciliation of non-IFRS loss for the year/period to loss for the year/period and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period to loss per share attributable to ordinary shareholders of the Company for the year/period.

About Genetron Holdings Limited

Genetron Holdings Limited ('Genetron Health' or the 'Company') (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as 'may', 'will,' 'expect,' 'anticipate,' 'target,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings

with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

5

Investor Relations Contact

US:

Hoki Luk

Head of Investor Relations

Email: hoki.luk@genetronhealth.com

Phone: +1 (408) 891-9255

David Deuchler, CFA

Managing Director | Gilmartin Group

ir@genetronhealth.com

Media Relations Contact

Yanrong Zhao

Genetron Health

yanrong.zhao@genetronhealth.com

Edmond Lococo

ICR

Edmond.Lococo@icrinc.com

Mobile: +86 138-1079-1408

genetron.pr@icrinc.com

6

GENETRON HOLDINGS LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS

For the three months ended For the six months ended
June 30, 2020 June 30, 2021 June 30,2020 June 30, 2021
RMB'000 RMB'000 US$'000 RMB'000 RMB'000 US$'000

Revenue

101,735 140,485 21,758 178,578 232,546 36,017

Cost of revenue

(37,512 ) (46,021 ) (7,128 ) (72,117 ) (83,533 ) (12,938 )

Gross profit

64,223 94,464 14,630 106,461 149,013 23,079

Selling expenses

(60,618 ) (88,516 ) (13,709 ) (114,442 ) (148,187 ) (22,951 )

Administrative expenses

(27,906 ) (54,577 ) (8,453 ) (49,529 ) (99,180 ) (15,361 )

Research and development expenses

(29,845 ) (56,162 ) (8,698 ) (57,474 ) (106,136 ) (16,438 )

Net impairment losses on financial and contract assets

(267 ) (3,474 ) (538 ) (990 ) (13,304 ) (2,061 )

Other income and gains/(losses) - net

1,270 8,081 1,252 (4,332 ) 8,611 1,335

Operating expenses

(117,366 ) (194,648 ) (30,146 ) (226,767 ) (358,196 ) (55,476 )

Operating loss

(53,143 ) (100,184 ) (15,516 ) (120,306 ) (209,183 ) (32,397 )

Finance income

198 9,447 1,463 228 5,179 802

Finance costs

(827 ) (1,409 ) (218 ) (4,375 ) (3,180 ) (493 )

Finance (costs)/income - net

(629 ) 8,038 1,245 (4,147 ) 1,999 309

Fair value loss of financial instruments with preferred rights

(2,778,591 ) - - (2,823,370 ) - -

Loss before income tax

(2,832,363 ) (92,146 ) (14,271 ) (2,947,823 ) (207,184 ) (32,088 )

Income tax expense

- - - - - -

Loss for the period

(2,832,363 ) (92,146 ) (14,271 ) (2,947,823 ) (207,184 ) (32,088 )

Loss attributable to:

Owners of the Company

(2,832,363 ) (91,820 ) (14,221 ) (2,947,823 ) (204,574 ) (31,684 )

Non-controlling interests

- (326 ) (50 ) - (2,610 ) (404 )
(2,832,363 ) (92,146 ) (14,271 ) (2,947,823 ) (207,184 ) (32,088 )

Loss per share attributable to ordinary shareholders of the Company

RMB RMB USD RMB RMB USD

-Basic and diluted

(17.04 ) (0.20 ) (0.03 ) (20.25 ) (0.45 ) (0.07 )

Loss per ADS attributable to ordinary shareholders of the Company

-Basic and diluted

(85.22 ) (1.00 ) (0.15 ) (101.23 ) (2.23 ) (0.35 )

Shares used in loss per share attributable to ordinary shareholders of the Company computation:

-Basic and diluted

166,179,400 459,903,803 459,903,803 145,604,263 458,999,227 458,999,227

ADS used in loss per ADS attributable to ordinary shareholders of the Company computation:

-Basic and diluted

33,235,880 91,980,761 91,980,761 29,120,853 91,799,845 91,799,845

7

GENETRON HOLDINGS LIMITED

UNAUDITED NON-IFRS FINANCIAL MEASURE

For the three months ended For the six months ended
June 30, 2020 June 30, 2021 June 30, 2020 June 30, 2021
RMB'000 RMB'000 US$'000 RMB'000 RMB'000 US$'000

Loss for the period

(2,832,363 ) (92,146 ) (14,271 ) (2,947,823 ) (207,184 ) (32,088 )

Adjustments:

Share-based compensation

9,903 12,504 1,937 14,954 21,754 3,369

Fair value loss of financial instruments with preferred rights

2,778,591 - - 2,823,370 - -

Non-IFRS Loss

(43,869 ) (79,642 ) (12,334 ) (109,499 ) (185,430 ) (28,719 )

Attributable to:

Owners of the Company

(43,869 ) (79,316 ) (12,284 ) (109,499 ) (182,820 ) (28,315 )

Non-controlling interests

- (326 ) (50 ) - (2,610 ) (404 )
(43,869 ) (79,642 ) (12,334 ) (109,499 ) (185,430 ) (28,719 )

Non-IFRS loss per share attributable to ordinary shareholders of the Company

RMB RMB USD RMB RMB USD

-Basic and diluted

(0.26 ) (0.17 ) (0.03 ) (0.75 ) (0.40 ) (0.06 )

Non-IFRS loss per ADS (5 ordinary shares equal to 1 ADS) attributable to ordinary shareholders of the Company

-Basic and diluted

(1.32 ) (0.86 ) (0.13 ) (3.76 ) (1.99 ) (0.31 )

Shares used in non-IFRS loss per share attributable to ordinary shareholders of the Company computation:

-Basic and diluted

166,179,400 459,903,803 459,903,803 145,604,263 458,999,227 458,999,227

ADS used in non-IFRS loss per ADS attributable to ordinary shareholders of the Company computation:

-Basic and diluted

33,235,880 91,980,761 91,980,761 29,120,853 91,799,845 91,799,845

8

GENETRON HOLDINGS LIMITED

UNAUDITED REVENUE AND SEGMENT INFORMATION

Diagnosis and
monitoring

- provision of
LDT services
RMB'000
Diagnosis and
monitoring

- sale of IVD
products
RMB'000
Development
services
RMB'000
Total
RMB'000

Three months ended June 30, 2020

Revenue

75,772 18,145 7,818 101,735

Segment profit

53,094 10,040 1,089 64,223

Three months ended June 30, 2021

Revenue

87,138 43,827 9,520 140,485

Segment profit

61,890 31,312 1,262 94,464

Six months ended June 30, 2020

Revenue

123,348 37,358 17,872 178,578

Segment profit/(loss)

81,749 25,388 (676 ) 106,461

Six months ended June 30, 2021

Revenue

158,966 59,093 14,487 232,546

Segment profit

110,701 36,534 1,778 149,013

9

GENETRON HOLDINGS LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As at December 31, 2020 As at June 30, 2021
RMB'000 RMB'000 US$'000

ASSETS

Non-current assets

Property, plant and equipment

76,891 76,746 11,886

Right-of-use assets

59,706 55,583 8,609

Intangible assets

12,265 15,284 2,367

Financial assets at fair value through profit or loss

19,609 36,334 5,628

Prepayments

15,362 23,418 3,627

Total non-current assets

183,833 207,365 32,117

Current assets

Inventories

24,971 32,978 5,108

Contract assets

1,112 2,188 339

Other current assets

36,500 31,255 4,841

Trade receivables

164,592 211,898 32,819

Other receivables and prepayments

42,420 46,835 7,254

Amounts due from related parties

214 225 35

Financial assets at fair value through profit or loss

140,294 142,194 22,023

Derivative financial instruments

196 745 115

Restricted cash

- 5,000 774

Cash and cash equivalents

1,375,766 1,066,815 165,229

Total current assets

1,786,065 1,540,133 238,537

Total assets

1,969,898 1,747,498 270,654

10

GENETRON HOLDINGS LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)

As at December 31, 2020 As at June 30, 2021
RMB'000 RMB'000 US$'000

LIABILITIES

Non-current liabilities

Borrowings

5,493 1,709 265

Lease liabilities

43,016 38,627 5,983

Other non-current liabilities

- 8,096 1,254

Total non-current liabilities

48,509 48,432 7,502

Current liabilities

Trade payables

34,071 36,172 5,602

Contract liabilities

8,417 9,719 1,505

Other payables and accruals

111,164 107,742 16,688

Amounts due to related parties

24 513 79

Borrowings

58,583 27,903 4,322

Lease liabilities

16,585 19,087 2,956

Derivative financial instruments

- 4,219 653

Total current liabilities

228,844 205,355 31,805

Total liabilities

277,353 253,787 39,307

Net assets

1,692,545 1,493,711 231,347

SHAREHOLDERS' EQUITY

Equity attributable to owners of the Company

Share capital

59 59 9

Share premium

6,657,562 6,680,307 1,034,648

Other reserves

(24,701 ) (49,917 ) (7,731 )

Accumulated losses

(4,940,375 ) (5,144,949 ) (796,851 )
1,692,545 1,485,500 230,075

Non-controlling interests

- 8,211 1,272

Total shareholders' equity

1,692,545 1,493,711 231,347

11

Disclaimer

Genetron Holdings Ltd. published this content on 24 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 August 2021 11:53:04 UTC.


ę Publicnow 2021
All news about GENETRON HOLDINGS LIMITED
09/27Genetron Health and IMPACT Therapeutics Announce Partnership to Drive Development of Sy..
GL
09/27Genetron Health and IMPACT Therapeutics Announce Partnership to Drive Development of Sy..
CI
09/16Genetron Health Unveils 13 Cancer Research findings at ESMO Congress 2021
GL
09/09GENETRON : September 2021 Corporate Presentation
PU
09/03GENETRON : to be Added to FTSE Global Equity Index Series Sept. 17
MT
09/03Genetron Added to FTSE Russell Global Equity Index Series
GL
09/03Genetron Holdings Limited Added to FTSE Russell Global Equity Index Series
CI
08/30Genetron Health's Co-Founder and Chief Scientific Officer Awarded International Prize f..
GL
08/24GENETRON : Narrows Q2 Loss as Revenue Rises
MT
08/24GENETRON : Health Reports Second Quarter 2021 Unaudited Financial Results (Form 6-K)
PU
More news
Financials (USD)
Sales 2021 95,1 M - -
Net income 2021 -64,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -38,9x
Yield 2021 -
Capitalization 1 210 M 1 210 M -
Capi. / Sales 2021 12,7x
Capi. / Sales 2022 8,58x
Nbr of Employees 799
Free-Float 84,0%
Chart GENETRON HOLDINGS LIMITED
Duration : Period :
Genetron Holdings Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENETRON HOLDINGS LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 13,62 $
Average target price 20,58 $
Spread / Average Target 51,1%
EPS Revisions
Managers and Directors
Si Zhen Wang Chief Executive Officer & Director
Ce Xu Chief Financial Officer
Wei-Wu He Chairman
Hai Yan Chief Scientific Officer & Director
Yu Chen Jiao Chief Technology Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
GENETRON HOLDINGS LIMITED-2.71%1 210
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414